The FDA on Thursday announced the second batch of companies being granted a “Commissioner’s National Priority Voucher,” a ticket to speedier reviews of drug candidates aligned with U.S. priorities. 

The announcement came as the Trump administration unveiled agreements with Eli Lilly and Novo Nordisk to reduce the prices of popular obesity drugs — part of a broader effort to show its interest in delivering medications to Americans faster, and at cheaper prices, than in the past.